- 1
- 2
Trove Therapeutics, Inc.
Trove is a semi-virtual biotech start-up located in Rockville, Maryland, USA, developing an advanced biologic asset and seeking funding and partners to conduct clinical trials in respiratory disease. We have data and drug supply on our lead, clinical-stage biologic asset to support up to 3 clinical trials in different respiratory conditions (2 x Phase 1b/2a in COVID and lung transplant; and 1 x Phase 2 in chronic sinusitis). Our biologic, called Therabron, is a replacement for a normally abundant native protein that is deficient in our targeted indications. Replacement therapies have a high approval rate with FDA (>70%) and patients with genetic deficiencies can be selected in some trials to increase our chances of demonstrating efficacy. Therabron was safe in 3 early studies. At present, the quickest path to an approval is likely an Emergency Use Authorization in severe COVID-19 patients, so we're looking for an initial $2M seed/Series A round to fund a Phase 1b/2a clinical trial then need another $16M to produce more drug and perform a convincing Phase 2 trial. We are already talking to several potential corporate partners, have signed one CDA with a top 5 pharma, and a relatively small amount of investment in clinical proof of concept demonstrations will attract at least one partner. Once clinical POC is established in targeted indications, we plan to exit via sale/acquisition or out-license. Our markets are large (3 products x >$1B each US) and deal comps in the respiratory space are $250M each and up. We can maximize our ROI by out-licensing the first indication and re-investing upfront license payment proceeds to advance the drug in further indications, depending on what happens in each field/indication and what we (management team and investors) decide to do.